OSAKA SODA (4046) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The company achieved a substantial increase in profit despite a decline in revenue, indicating that the results were driven by improved profitability. Revenue declined to ¥736.9B (-1.3% YoY), while Operating Income increased substantially to ¥129.4B (+21.6%), Ordinary Income to ¥146.2B (+24.9%), and Net Income to ¥106.4B (+34.1%). The primary factor behind the profit increase was improved profitability in the Basic Chemicals segment, while temporary factors, including gains on sales of investment securities, also contributed to some extent to the growth rate of Net Income.

Factors Affecting Performance

【Revenue】Revenue was ¥736.9B, down 1.3% YoY. By segment, Basic Chemicals increased revenue to ¥308.4B (+9.7%), while Functional Chemicals declined to ¥206.0B (-10.9%) and Trading and Other Businesses declined to ¥118.7B (-12.4%). Healthcare posted a solid increase in revenue to ¥103.8B (+5.1%). By region, Japan declined to ¥447.0B (-2.1%) and Europe to ¥55.7B (-16.1%), while Asia grew to ¥99.1B (+22.6%).

【Profit and Loss】Operating Income was ¥129.4B (+21.6%), and the Operating Margin expanded to 17.6% from approximately 14.3% in the same period of the previous year, an increase of approximately 3.3pt. The main improvement came from the Basic Chemicals segment, whose segment profit surged to ¥47.3B (+138.4%), with its margin improving by approximately 8.3pt from 7.1% to 15.3%. Ordinary Income was ¥146.2B, boosted by ¥18.2B in non-operating income, including ¥10.7B in dividend income and ¥3.6B in foreign exchange gains. Net Income was ¥106.4B (+34.1%), while pretax income benefited from ¥9.2B in extraordinary income, including ¥6.1B in gains on sales of investment securities. The company achieved profit growth despite declining revenue; in conclusion, it recorded a decline in revenue but an increase in profit.

Segment Analysis

Healthcare accounted for the largest share of segment profit at 36.6% (¥51.0B), making it the largest profit-contributing business. Basic Chemicals recorded revenue of ¥308.4B (+9.7%) and segment profit of ¥47.3B (+138.4%), representing substantial profit growth, with its margin improving from 7.1% to 15.3%. Functional Chemicals recorded revenue of ¥206.0B (-10.9%) and segment profit of ¥33.3B (-9.2%), maintaining a margin of 16.2%, broadly in line with the previous year. Healthcare recorded revenue of ¥103.8B (+5.1%) and segment profit of ¥51.0B (+0.8%), while its margin declined by approximately 2.1pt from 51.3% to 49.2%. Trading and Other Businesses recorded revenue of ¥118.7B (-12.4%) and segment profit of ¥7.7B (-9.8%), with a relatively low margin of 6.5%. Corporate expenses increased to ¥9.9B (¥9.3B in the previous year), but the increase in total segment profit more than offset this rise.

Key Financial Metrics

【Profitability】The Operating Margin of 17.6% and Net Profit Margin of 14.4% both improved from approximately 14.3% and approximately 10.6%, respectively, in the same period of the previous year, indicating a clear improvement in profitability.【Cash Flow Quality】Accounts receivable were ¥284.1B and inventories were ¥95.5B, indicating substantial balances and a high level of working capital.【Investment Efficiency】ROE was 8.7%; despite the high Net Profit Margin, the low total asset turnover and financial leverage are limiting factors.【Financial Soundness】The Equity Ratio was 75.4%. The Current Ratio, calculated from current assets of ¥951.3B and current liabilities of ¥312.0B, was approximately 304.9%, indicating a conservative financial foundation. Interest-bearing debt was concentrated in short-term borrowings of ¥71.7B, resulting in a short-term-biased maturity profile.

Cash Flow Analysis

Although the cash flow statement was not disclosed, an analysis of funding trends based on changes in the balance sheet shows that cash and deposits were ¥161.5B, broadly flat from ¥163.4B in the same period of the previous year. The company held ¥249.7B in short-term investment securities, providing substantial liquidity resources including cash equivalents. Meanwhile, accounts receivable and notes receivable were ¥284.1B and inventories were ¥95.5B, indicating that both working capital items tying up funds had accumulated. Retained earnings were ¥840.3B, an increase of ¥78.7B from ¥761.5B in the same period of the previous year, indicating continued accumulation of retained earnings. On a net basis against accounts payable of ¥157.7B, the combined balance of accounts receivable and inventories substantially exceeded accounts payable. Although the funds tied up in working capital remain within a range that does not impair financial soundness, there is room for improvement from the perspective of capital efficiency.

Earnings Quality

Ordinary Income was ¥146.2B compared with Operating Income of ¥129.4B. The ¥16.8B difference was attributable to non-operating income, primarily dividend income of ¥10.7B and foreign exchange gains of ¥3.6B, and can be understood as part of recurring earning power. Meanwhile, pretax income of ¥152.3B included ¥9.2B in extraordinary income, including ¥6.1B in gains on sales of investment securities, and ¥3.1B in extraordinary losses, resulting in a net gain of ¥6.1B, equivalent to 5.7% of Net Income of ¥106.4B. Due to these non-recurring items, the 34.1% YoY increase in Net Income exceeded the 21.6% increase in Operating Income. Accordingly, when evaluating earning power, greater emphasis should be placed on improvements on an Operating Income and Ordinary Income basis. Comprehensive income was ¥147.2B, exceeding Net Income of ¥106.4B, mainly due to the recognition of ¥40.4B in valuation differences on securities.

Earnings Forecast and Guidance

Progress against the full-year company forecasts was 72.2% for Revenue, 74.8% for Operating Income, 78.2% for Ordinary Income, and 78.8% for Net Income. Revenue progress was slightly below the standard 75%, while profit-related indicators were generally in line with or above the standard level. The company is compensating for sluggish revenue growth through margin improvement. Revenue of ¥283.1B and Operating Income of ¥43.6B will be required in Q4. If the Operating Margin of 17.6% through Q3 is maintained, the full-year profit forecasts appear achievable.

Shareholder Returns

The Q2 dividend was ¥12.00 per share. The full-year dividend forecast is ¥25.00 per share. Based on the full-year EPS forecast of ¥108.28, the projected Payout Ratio is approximately 23.1%, calculated based solely on dividends. Given the financial foundation of retained earnings of ¥840.3B and an Equity Ratio of 75.4%, the company is considered to have substantial financial capacity to sustain dividend payments.

Risk Factors

1. Sustainability of profitability improvement in Basic Chemicals: The Basic Chemicals segment’s profit margin improved by approximately 8.3pt YoY and was the primary driver of consolidated profit growth. Given the magnitude of the improvement, it is necessary to monitor the risk of a reversal due to raw material and energy prices or supply and demand trends.

2. Working capital efficiency: Accounts receivable and notes receivable of ¥284.1B and inventories of ¥95.5B are substantial, tying up funds in working capital. If the decline in revenue in Functional Chemicals and Trading and Other Businesses continues, inventories and receivables may remain outstanding for longer periods.

3. Reliance on short-term borrowings: Interest-bearing debt is concentrated in short-term borrowings of ¥71.7B, resulting in a short-term-biased maturity profile. Liquidity is substantial, with cash and deposits of ¥161.5B and short-term investment securities of ¥249.7B, and resilience is high at present; however, changes in the financial environment warrant close monitoring.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Margin and Net Profit Margin significantly exceeded the industry median, indicating that profitability is at a superior level within the industry.

Growth and Capital Efficiency

The Revenue Growth Rate was below the industry median, indicating that top-line growth is relatively weaker within the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Despite the decline in revenue, the company maintained an Operating Margin of 17.6% and a Net Profit Margin of 14.4%, clearly improving profitability from the same period of the previous year. Improved profitability in Basic Chemicals was the primary driver of consolidated profit growth.

2. Progress toward the full-year Operating Income forecast was 74.8%, close to the standard level, while Net Income progress was 78.8%, above the standard level. Revenue progress remained at 72.2%, making a recovery in Q4 critical to achieving the revenue plan.

3. Net Income benefited from a net extraordinary gain of ¥6.1B, including a gain on sales of investment securities of ¥6.1B. When evaluating the 34.1% YoY increase in Net Income, it is useful to also assess the improvement on an Operating Income and Ordinary Income basis.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,022–¥1,083 at ±1% for the Cost of Equity, and ¥1,050–¥1,054 at ±0.1 for ω.

Notes:

• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because non-controlling interests are included in net assets, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 results were strong, with substantial profit expansion despite a modest revenue decline. Revenue fell 1.3% year on year to ¥73.69bn. Operating income rose 21.6% to ¥12.94bn, lifting the operating margin to 17.6% from 14.3% a year earlier. Gross profit increased to ¥24.61bn from ¥21.99bn, and the gross margin expanded by approximately 394bp to 33.4%. SG&A expense increased only 2.9% to ¥11.67bn, materially below the pace of gross-profit growth, demonstrating favorable operating leverage. Net income attributable to owners rose 34.0% to ¥10.64bn. Net margin improved by approximately 380bp to 14.4% from 10.6%. The Basic Chemicals segment was the principal earnings driver, with segment profit increasing 138.4% year on year to ¥4.73bn. Healthcare remained the largest contributor to segment profit at ¥5.10bn, although its segment margin moderated. Functional Chemicals experienced lower revenue but preserved a comparatively high segment margin. Ordinary income of ¥14.62bn was supplemented by ¥1.07bn of dividend income and ¥0.37bn of foreign-exchange gains. Profit before tax also included a net ¥0.61bn extraordinary gain, principally from investment-security sales. The balance sheet remains highly liquid, with a 304.9% current ratio and cash exceeding short-term borrowings by 2.25x. However, the 100% short-term-debt ratio creates a refinancing concentration, notwithstanding ample liquidity. Manufacturing working-capital efficiency requires attention, as annualized receivable days of 106 and inventory days of 98 are elevated. Full-year operating-income progress is 74.8%, broadly in line with the standard 75% Q3 progress rate, indicating that the current forecast is well supported by the cumulative result. The key issue into Q4 is whether improved gross profitability can be retained while receivables and inventories are normalized.

Profitability Analysis

Reported annualized ROE is 11.5%, a good level under the stated benchmark but below the 15% threshold associated with excellent returns. The DuPont decomposition is net profit margin of 14.4% × asset turnover of 0.603x × financial leverage of 1.33x. Return generation is therefore driven primarily by a high margin rather than aggressive leverage, as the balance sheet is predominantly equity funded. The most notable earnings change was margin expansion: gross margin rose to 33.4% from 29.5%, while operating margin rose approximately 331bp to 17.6%. This improvement was reinforced by cost discipline, because SG&A increased 2.9% while revenue declined 1.3%. Basic Chemicals produced the largest incremental profit, with segment profit rising ¥2.75bn to ¥4.73bn and segment margin improving to 15.3% from 7.1%. Functional Chemicals revenue declined 10.9% to ¥20.60bn and segment profit declined 9.2% to ¥3.33bn, but its segment margin improved modestly to 16.2%. Healthcare revenue grew 5.1% to ¥10.38bn and segment profit was broadly stable at ¥5.10bn; its 49.2% margin remained the highest among reported segments, though down from 51.3%. Trading and other revenue declined 12.4% to ¥11.87bn and segment profit fell 9.8% to ¥0.77bn, leaving a low 6.5% margin. Unallocated corporate expenses increased to ¥0.99bn from ¥0.93bn, reflecting spending including basic research and development not allocated to segments. The five-factor analysis indicates a 69.9% tax burden and an interest burden of 1.177x, with the latter reflecting net non-operating financial income rather than financial stress. Interest coverage of 123.21x confirms that financing cost is immaterial to current earnings. Non-operating income was 2.5% of revenue and therefore does not exceed the 5% materiality threshold, although dividend income of ¥1.07bn remains a meaningful contributor to ordinary income.

Growth Assessment

Revenue contraction was limited to 1.3%, while operating profit growth of 21.6% shows that the earnings recovery was driven by mix, gross-margin improvement and expense leverage rather than top-line expansion. Basic Chemicals revenue increased 9.7% to ¥30.84bn and was the main source of consolidated profit growth. Healthcare also expanded revenue by 5.1%, providing a stable high-margin earnings base. Functional Chemicals and Trading and other together reduced revenue by ¥4.19bn year on year, demonstrating that growth remains uneven across the portfolio. By geography, Japan revenue declined 2.1% to ¥44.70bn, China declined 4.9% to ¥9.83bn, Europe declined 16.1% to ¥5.57bn, and other regions declined 6.7% to ¥3.68bn. Asian revenue excluding the disclosed China category increased 22.6% to ¥9.91bn, supported by stronger Basic Chemicals and Healthcare sales. The full-year sales forecast is ¥102.00bn, implying Q4 revenue of ¥28.31bn; Q3 cumulative progress is 72.2%, 2.8 percentage points below the standard 75% level. Full-year operating-income guidance is ¥17.30bn, implying Q4 operating income of ¥4.36bn; cumulative progress of 74.8% is essentially aligned with the standard Q3 pace. Ordinary-income progress is 78.2% against the ¥18.70bn forecast, while net-income progress is 78.8% against the ¥13.50bn forecast. The implied Q4 net income of ¥2.86bn is materially below the Q3 cumulative run rate, consistent with a prudent forecast that leaves room for normal seasonality or reduced non-operating and extraordinary contributions. The forecast calls for full-year revenue growth of 5.8% and operating-income growth of 30.6%, requiring a return to top-line growth in the final quarter.

Financial Health

Financial health is strong, supported by total equity of ¥122.95bn against total liabilities of ¥40.02bn. The equity ratio is 75.4%, while debt-to-equity is a conservative 0.33x and debt-to-capital is only 5.5%. The current ratio of 304.9% and quick ratio of 274.3% indicate substantial near-term liquidity. Working capital totals ¥63.94bn. Cash and deposits of ¥16.15bn alone cover short-term loans of ¥7.17bn by 2.25x, and short-term investment securities of ¥24.97bn provide additional liquidity capacity. The principal maturity consideration is that 100% of reported interest-bearing debt is short-term. This refinancing-risk alert reflects maturity concentration rather than a lack of repayment capacity, since current assets of ¥95.13bn significantly exceed current liabilities of ¥31.20bn. Accounts payable increased ¥2.65bn year on year to ¥15.77bn, partially financing higher working-capital requirements. Retained earnings increased ¥7.88bn to ¥84.03bn, strengthening internally generated capital. Treasury stock increased in absolute deduction by ¥4.61bn to negative ¥11.02bn, indicating a material capital-allocation action that reduced reported equity relative to a no-buyback case. Investment securities increased ¥5.05bn to ¥34.36bn and account for 21.1% of total assets; this creates sensitivity of comprehensive income and net assets to market-value movements. Valuation differences on securities increased ¥4.04bn during the period, contributing to total comprehensive income of ¥14.73bn, above net income of ¥10.64bn. Asset retirement obligations total ¥0.66bn, equivalent to approximately 1.6% of liabilities, a manageable disclosed environmental obligation for a chemical manufacturer. Goodwill is only ¥0.84bn, or 0.1% of equity, leaving negligible goodwill-impairment exposure.

Notable B/S Changes

Investment securities: +¥50.53bn (+17.7%) to ¥343.63bn - exceeds the ¥50bn absolute-change threshold; raises exposure of equity and comprehensive income to securities-market valuation movements. Treasury stock: -¥46.11bn in carrying value (-71.9%) to -¥110.21bn - material increase in the equity deduction, indicating significant shareholder-capital allocation and reducing equity relative to retained earnings. Intangible assets: +¥7.38bn (+48.5%) to ¥22.59bn - increased intangible-asset base, though it remains modest at 1.4% of total assets. Goodwill: -¥0.34bn (-28.8%) to ¥0.84bn - goodwill exposure remains immaterial at 0.1% of equity, limiting impairment risk. Construction in progress: +¥9.82bn (+49.6%) to ¥29.61bn - indicates a larger manufacturing investment pipeline and raises the importance of project completion, commissioning and return-on-investment execution. Accounts payable: +¥26.52bn (+20.2%) to ¥157.69bn - increased supplier financing partly offsets higher receivables and inventory, but should be monitored with working-capital turnover.

Cash Flow Quality

The earnings-quality assessment is supported by operating-profit expansion, strong gross-margin improvement and limited interest-cost burden. Net income includes a net extraordinary gain of ¥0.61bn, comprising ¥0.61bn gain on sales of investment securities, ¥0.31bn gain on transfer of business and ¥0.31bn extraordinary losses. The net extraordinary contribution represents approximately 5.7% of net income, which is below the 20% level associated with a material one-time earnings warning. Dividend income of ¥1.07bn and foreign-exchange gains of ¥0.37bn also supported ordinary income, although core operating income remained the dominant profit source at ¥12.94bn. Working-capital quality is the main area requiring monitoring. Annualized DSO of 106 days exceeds the 60-day warning threshold, indicating slower cash collection or a customer and sales-mix profile that ties up capital. Annualized DIO of 98 days also exceeds the 90-day warning threshold and may indicate elevated finished-goods carrying levels or slower inventory conversion. These two quality alerts increase the risk that accounting earnings convert less efficiently into operating cash during the final quarter. Accounts receivable were ¥28.41bn and electronically recorded monetary claims were ¥6.29bn, so the receivables exposure is material relative to revenue. Raw materials were ¥4.61bn and work in process was ¥3.39bn, while finished goods were ¥9.55bn; the finished-goods balance is the largest disclosed inventory category. Construction in progress increased to ¥2.96bn from ¥1.98bn, indicating an active manufacturing investment pipeline that should be monitored for execution and return discipline.

Dividend Sustainability

The company paid an interim dividend of ¥12.00 per share at Q2. The calculated payout ratio based on the disclosed interim dividend and Q3 cumulative earnings is 15.1%, which is conservative. The full-year dividend forecast is ¥25.00 per share, equivalent to an implied payout ratio of approximately 23.1% against forecast EPS of ¥108.28. This is well below the 60% dividend-payout benchmark and leaves substantial earnings retention capacity. Retained earnings of ¥84.03bn provide a substantial capital buffer. The low debt-to-capital ratio of 5.5%, strong current liquidity and interest coverage of 123.21x also support financial flexibility. The increase in treasury stock indicates that shareholder returns may also include repurchases, but a total return ratio cannot be quantified from the disclosed information. Dividend sustainability will depend particularly on preserving the current margin gains and converting the elevated receivable and inventory balances into cash.

Risk Assessment

Business risks include Chemical-market and product-mix risk: the strong Basic Chemicals profit recovery is important to consolidated growth, but chemical pricing, feedstock costs and demand cycles can reverse margin gains., Regional demand risk: revenue declined in Japan, China, Europe and other regions, while growth was concentrated in Asia; a broader recovery is needed to deliver the full-year sales-growth forecast., Functional Chemicals risk: segment revenue declined 10.9% and segment profit declined 9.2%, making demand stabilization in this business important., Inventory risk: annualized DIO of 98 days exceeds the 90-day warning level and may expose the company to slower demand, price declines, inventory write-downs or production-adjustment risk., Environmental and operational risk: chemical manufacturing carries environmental-compliance, safety and asset-retirement obligations; disclosed asset retirement obligations are ¥0.66bn..

Financial risks include Refinancing-risk alert: 100% of interest-bearing debt is short-term. Liquidity is ample, but debt maturity is concentrated and requires continued access to short-term funding markets., Receivables-collection risk: annualized DSO of 106 days exceeds the 60-day alert threshold, increasing working-capital intensity and potential credit exposure., Market-value risk: investment securities of ¥34.36bn represent 21.1% of total assets, and securities valuation movements materially affect comprehensive income and equity., Non-core income sensitivity: dividend income, foreign-exchange gains and gains on investment-security sales supported pre-tax profit, making reported net income somewhat more sensitive to financial-market conditions than operating income..

Key concerns include The highest-priority operational issue is normalization of receivable and inventory days, because both metrics are above stated warning thresholds and can weaken cash conversion., The most important earnings-monitoring issue is the sustainability of Basic Chemicals margin recovery, which generated the largest year-on-year segment-profit increase., The short-term debt ratio is high by maturity composition, although its impact is moderated by cash coverage of 2.25x, short-term investment securities and a 304.9% current ratio., The full-year forecast requires Q4 revenue growth after a 1.3% cumulative revenue decline, even though operating-profit guidance is already substantially supported by Q3 progress..

Investment Implications

Key takeaways include Operating performance improved materially: operating income increased 21.6% despite a 1.3% revenue decline, driven by gross-margin expansion and controlled SG&A growth., The business mix is favorable, with Healthcare delivering the highest segment margin and Basic Chemicals providing the largest incremental earnings contribution., The capital structure is conservative, with 75.4% equity ratio, 0.33x debt-to-equity and 123.21x interest coverage., High DSO and DIO are the principal financial-quality issues and should be assessed alongside the evolution of receivables, finished goods and payables., FY2026 operating-income guidance appears achievable based on 74.8% Q3 progress versus the standard 75% pace..

Metrics to watch include Basic Chemicals segment revenue, segment margin and profit sustainability, Functional Chemicals revenue recovery and segment-profit trend, Annualized receivable days and inventory days, Short-term debt rollover and cash-to-short-term-debt coverage, Investment-securities balance and valuation difference on securities, Q4 revenue needed to achieve the ¥102.00bn full-year forecast, Margin contribution from non-operating dividend income, foreign exchange and investment-security gains.

Regarding relative positioning, The company combines an excellent 17.6% operating margin, 14.4% net margin and good 11.5% annualized ROE with a notably conservative balance sheet. Its financial-risk profile is lower than that of highly leveraged manufacturers, but working-capital efficiency is weaker than the stated manufacturing benchmarks, and earnings momentum is concentrated in Basic Chemicals while Functional Chemicals and Trading and other remain under revenue pressure.